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e-mail address: dr.alsabaani@kku.edu.sa (N. Al Sabaani).Nasser Al Sabaani, MD ⇑; Abdullah Al Assiri, MD; Abdullah Al Torbak, MD; Saeed Al Motawa, MDAbstractPurpose: To assess the safety and efficacy of the implantable contact lens (ICL™) to treat myopia.
Design: Clinical, retrospective, single center, non-randomized case series.
Participants: Sixty-nine eyes of 46 patients with myopia ranging from 3.00 to 25.00 D were included in this study.
Intervention: Implantation of the ICL™.
Main outcome measures: Uncorrected Visual Acuity (UCVA), refraction, best spectacle corrected visual acuity (BSCVA), adverse
events, operative and postoperative complications, subjective assessment and symptoms.
Results: The mean follow-up was 12.35 ± 6.13 (SD) months (range, 6 months–32 months). At the last visit, 49.20% of eyes had 20/
20 or better UCVA compared to preoperative 20/20 or better BSCVA of 31.9% of eyes; 69.23% of eyes had postoperative UCVA
better than or equal to preoperative BSCVA. The mean manifest refractive cylinder was 1.93 ± 1.21 D at baseline and
1.00 ± 0.92 D postoperatively. The mean manifest refraction spherical equivalent (MRSE) was 11.70 ± 4.24 D preoperatively
and 0.69 ± 1.13 D postoperatively. A total of 69.8% of eyes were within ±0.5 D of the predicted MRSE; 84.1% were within
±1.0 D, and 88.90% were within ±2.0 D. BSCVA of 20/20 or better was achieved in 64.6% of eyes postoperatively, compared
to 31.9% preoperatively. Mean improvement in BSCVA was 1line. One eye (1.5%) lostP2 lines of BSCVA at the last visit, whereas
20% of eyes improved byP2 lines. A total of 56.92% of cases gainedP1 line of BSCVA and 4.62% of cases lostP1 line. Four ICL
lenses were removed without significant loss of BSCVA, and 2 eyes with clinically significant lens opacities were observed. Four
eyes (5.8%) developed a pupillary block the first day postoperatively. One eye (1.4%) developed a hypotony and AC shallowing.
Conclusion: Implantation of ICL for the correction of myopia was a safe procedure with good visual and refractive results from the
early postoperative period to 1 year. Long-term follow-up is required to confirm the long-term safety of this implant.
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Refractive surgery confers visual freedom from the use of
spectacles and contact lenses. Spectacles continue to be a
natural and simple aid in correcting refractive errors. How-
ever, many adults with myopia are unwilling and unable to
use spectacles due to discomfort from their refractive errorand poor quality of vision. The higher the refractive error,
the higher the percentage of people who are dissatisfied with
the quality of vision with spectacles. Although spectacles or
contact lenses are successful, there are several factors that
indicate that a permanent solution from refractive surgery
should be considered. These include aging with the develop-
ment of nuclear sclerosis in the lens, contact lens intolerance,e:
al.com
Arabia.
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correction of varying magnitudes of myopia has progressed
over the past decade. Various techniques, some complemen-
tary and some overlapping, can predictably, safely and per-
manently treat low, moderate and high myopia.1–7 Corneal
surgery shows the greatest promise but is controversial for
higher corrections because of increased tissue removal, small
ablation zones, increased aberrations, and poor predictabil-
ity.9–14 Clear lens extraction for high and extreme myopia ex-
poses the patient to the risk of retinal detachment and
cystoid macular edema (CME).15 This is true for cataract pa-
tients and younger patients undergoing elective clear lens
extraction. In younger patients clear lens extraction elimi-
nates accommodation, and intraocular lens (IOL) power cal-
culations are not as predictable.16,17
The concept of a phakic IOL for myopia was developed in
the late 1950s with the design of a single-piece poly(methyl
methacrylate) plate-haptic IOL that was fixated in the anterior
chamber angle. The long-term data showed a significant inci-
dence of corneal decompensation and uveitis–glaucoma–hy-
phema syndrome, thus, these IOLs were abandoned.18
The Worst iris-claw lens and Baikoff anterior chamber IOL
in the middle 1980s resulted in a resurgence of interest in the
phakic IOLs.5–8 In 1986, Fyodorov developed a new posterior
chamber IOL made of silicone for phakic, highly myopic
patients.19 However, implantation of this lens led to a high
incidence of cataract.20 In 1993, Staar Surgical (A.G. Nidau)
introduced a modified phakic posterior chamber intraocular
lens (PPC IOL), the implantable contact lens (ICL), for the cor-
rection of high myopia. ICL has undergone at least 4 designs
iterations with several studies reporting good refractive out-
comes and optical performance.21–33
The Visian Implantable Collamer Lens (ICL) was granted
approval by the United States Food and Drug Administration
(FDA) in December 2005 for commercial use in the United
States for spherical myopia of 3.00–20.00 diopters (D). The
Toric Implantable Collamer Lens (TICL) represents an expan-
sion of the earlier Visian ICL study and is currently awaiting
approval in the United States. In this paper, we evaluate
the efficacy and safety of the ICL implantation for myopia.Patients and methods
This retrospective study evaluated 69 eyes of 46 consecu-
tive patients who underwent implantation of a phakic IOL
(ICL) to correct myopia from January 2007–31 December
2009 at the King Khaled Eye Specialist Hospital, Riyadh, King-
dom of Saudi Arabia. Study approval was obtained from the
institutional review board. The target postoperative spherical
(SE) refraction was emmetropia. Inclusion criteria were age
between 21 and 45 years, with no restrictions in gender or
race, myopia between 3.00 and 25.00 D, best spectacle-
corrected visual acuity (BSCVA) of better than or equal to
20/100 for the spherical ICL and 20/40 or better for the toric
ICL, no preexisting ocular pathology, no previous surgery ex-
cept for astigmatic keratotomy, no systemic disease, contact
lens intolerance, anterior chamber depth (ACD) of 2.80 mm
or more (measured from the corneal endothelium to the
anterior lens capsule), and endothelial cell count greater than
2000 cells/mm2.
An ophthalmic examination was performed before surgery
and postoperatively at 2–4 h, 1 day and 1, 3, 6 months andthe last visit. The examinations included distance uncorrected
visual acuity (UCVA) and distance BSCVA using a Snellen
chart, manifest and cycloplegic refractions, slitlamp and fun-
dus evaluations, applanation tonometry, corneal topography,
central pachymetry, horizontal corneal diameter (white-to-
white), anterior chamber depth (ACD) and corneal endothe-
lial cell count (cells/mm2).
The ICL is a plate-haptic single-piece lens designed for
implantation in the posterior chamber with support on the cil-
iary sulcus. It is made of collamer, a flexible, hydrophilic
material derived from collagen that is a copolymer compris-
ing hydrophilic collagen and HEMA. It is 6.0 mm wide and
comes in 5 d (11.0, 11.5, 12.0, 12.5, and 13.0 mm). The lens
has a central convex–concave optic zone with a diameter of
4.5–5.5 mm, depending on dioptric power. The ICL design
has been modified many times. In this study, all patients
had implantation of the ICM V4 model, which is presumed
to offer better vaulting over the crystalline lens than the
ICM V3 because the optical zone has greater convex–con-
cave curvature. Lens power calculations were performed with
formulas developed by Staar. The variables in the formula
were preoperatively manifested and cycloplegic refractions,
average keratometric power, corneal thickness, and central
ACD. The length of the implanted ICL was determined based
on the patient’s horizontal corneal diameter (white to white).Statistical analysis
Statistical analysis was performed with Epi info software
(Centers for Disease Control and Prevention, Atlanta, GA,
USA). Postoperative data were compared with the Student’s
t-test. Results were considered statistically significant when
P < 0.05.Results
Patient population
The study cohort comprised, 69 eyes of 46 patients
with a mean patient age of 27.5 years ± 5.7 (SD) (range,
21–44 years). Twenty-four of the 46 patients were female
(52.2%). The mean follow-up, was 12.35 ± 6.13 months
(range 6–32 months). The mean preoperative sphere was
10.85 ± 4.0D (range 4.00 to 23.75). The mean cylinder
was 1.93 ± 1.21 D (range, 0.00 to 5.50 D) preoperatively
and 1.00 ± 0.92 D (range 0.00 to 4.75 D) postoperatively.
The mean SE was 11.70 ± 4.24 D (range 4.75 to
25.25 D) preoperatively and 0.69 ± 1.13 D (range 0.25
to 5.125 D) postoperatively (P = 0.000). Two (2 patients)
of the 69 eyes (2.8%) in this study were amblyopic, and 1
(1.40%) eye had an inferior paracentral scar. Fifty-nine eyes
(85.4%) had a myopic fundus,1 eye(1.4%) with a tilted disc.
One (1.4%) eye had a history of prior intracorneal ring
insertion and removal.UCVA
There was a statistically signficant increase in mean UCVA
from 20/400 preoperatively to 20/25 at the last postoperative
visit (P < 0.0001). The preoperative UCVA was 20/100 or
worse in 98.2%, no eyes (0%) were 20/40 or better, with only
Outcome of phakic ICL for myopia 261one eye (2.10%) 20/50 or better uncorrected at the baseline
(Fig. 1).
At the last postoperative visit, mean UCVA improved by
12 lines. The UCVA improved to 20/20 or better in 49.20%
of patients and the proportion of eyes with 20/40 or better
was 86.2%. No eyes lost UCVA. Fig. 2 presents the stability
of UCVA (P > 0.05 between each postoperative interval).Figure 2. The change in mean uncorrected visual acuity (UCVA) (Stability)
at 1 day (55 eyes), 4 weeks (65 eyes), 3 months (34 eyes), 6 months (36
eyes), last visit (65 eyes) postoperatively for implantable collamer lens
surgery for myopia. Acuity data are in LogMAR units.Preoperative best spectacle-corrected acuity (BSCVA)
versus postoperative uncorrected visual acuity
Fig. 3 presents last postoperative visit UCVA compared to
preoperative BSCVA. Comparing the proportion of eyes with
20/20 or better acuity, only 31.9% of eyes had this level of
BSCVA preoperatively, compared with 49.2% of eyes with
this level of UCVA at the last postoperative visit. Similarly,
at the last examination 64.6% of eyes had 20/25 or better
UCVA, compared with 55.1% BSCVA at baseline. Eighty-six
percent of eyes achieved 20/40 or better UCVA at the last
visit postoperatively, whereas 97% of eyes had 20/40 or bet-
ter BSCVA preoperatively. Postoperative UCVA in 69.23% of
eyes was equal to or better than preoperative BSCVA. The
proportion of eyes that presented with preoperative
BSCVA < 20/20 yet had postoperative UCVAP 20/20 was
23.07%. This difference was statistically signficant (P =
0.0012).Figure 3. Preoperative (pre-op) best spectacle-corrected visual acuity
(BSCVA) versus last postoperative visit uncorrected visual acuity (UCVA)
for implantable collamer lens surgery for myopia.Refractive outcomes
Manifest refractive spherical equivalent (MRSE)
There was statistically signficant decrease in mean MRSE
from 11.70 ± 4.24 D (range, 4.75 to 25.25 D) preopera-
tively to 0.69 ± 1.13 D (range, 0.25 to 5.125 D) postop-
eratively (P < 0.0001). Only 7.20% of eyes had preoperative
myopia 67.0 D, 73.9% of eyes were between 7 and
15 D and 18.8% of eyes had >15 D myopia (Fig. 4). At
baseline, no eyes (0%) fell within ±1.00 D MRSE compared
with 84.1% at the last postoperative visit.
Table 1 presents the predictability for all eyes in the study
cohort. At the last postoperative visit, 69.8% of eyes were
within ±0.50 D and 84.10% were within ±1.0 D.Figure 1. Preoperative (pre-op) uncorrected visual acuity (UCVA) versus las
underwent implantable collamer lens surgery for myopia. P < 0.05 indicates sPredictability outcomes stratified by preoperative
MRSE
Table 2 presents predictability stratified according to pre-
operative MRSE into three groups: 67 D, 7 to 15 D, and
>15 D. At the last postoperative visit, 100% of eyes in the
<7 D group fell within ±1.0 D of their attempted correction,
89.4% in the 7 to 15 D group, and 54.6% in the >15D
group. Predictability outcomes within ±0.50 D were: 100%t postoperative visit uncorrected visual acuity (UCVA) for 69 eyes that
tatistical significance.
Figure 4. Myopia was stratified based on preoperative (pre-op) versus
last visit postoperatively manifest refractive spherical equivalent for 69
eyes that underwent implantable collamer lens surgery for myopia.
Table 2. Predictability of manifest refraction attempted vs. achieved
stratified by preoperative MRSE.
Predictability Myopia 6 7 Myopia 7.0 to
15
Myopia > 15
±0.50 5/5(100%) 35/47(74.5%) 4/11(36.4%)
±1.00 0/5(0.00%) 7/47(89.4%) 2/11(54.6%)
±2.00 0/5(0.00%) 2/47(93.7%) 1/11(63.7%)
±3.00 0/5(0.00%) 2/47(98% 2/11(81.9%)
±5.00 0/5(0.00%) 1/47(100%) 2/11(100%)
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group).Figure 5. Preoperative (pre-op) versus last visit postoperatively best
spectacle-corrected visual acuity (BSCVA) for 69 eyes that underwent
implantable collamer lens surgery for myopia.
Figure 6. Preoperative versus last visit postoperative change in best
spectacle-corrected visual acuity (BSCVA) for 69 eyes that underwent
implantable collamer lens surgery for myopia.BSCVA
Mean improvement in postoperative BSCVA was 1 line
compared to preoperatively. At the last postoperative visit,
64.6% of eyes had a BSCVA of 20/20 or better compared
with only 31.9% preoperatively (Fig. 5). BSCVA of 20/30 or
better improved from 79.7% preoperatively to 95.4% at the
last postoperative visit. Postoperative BSCVA was higher
than or equal to preoperative BSCVA in 95.4% eyes. The pro-
portion of eyes that presented with preoperative BSCVA <
20/20 with an increase in postoperative BSCVAP 20/20
was 32.3%. This outcome was statistically significant
(P = 0.0000471). There was increase of P2 lines in 20% of
eyes and one eye (1.5%) lost P2 lines of BSCVA at the last
postoperative visit (Fig. 6).
Loss of P2 lines of BSCVA occurred in a 34-year-old
female with 11.75 D of myopia and 20/30 BSCVA preoper-
atively. Postoperative examination indicated a decentred ICL
with low vault (80 um) that developed an anterior subcapsular
catatract. On the last visit her BSCVA was 20/60. Two eyes
(3%) lost 1 line of BSCVA 6 months or later. No eyes had
vision worse than 20/100 preoperatively or at any postoper-
ative visit.Complications
Surgical complications
The ICL haptic was torn during surgery in three cases
(4.3%). In one additional case (1.4%) the ICL cracked during
surgery. None of these cases had a loss of BSCVA. No other
significant surgical complications occurred.Table 1. Predictability of manifest refraction attempted vs. achieved in
patients with an implantable collamer lens for myopia.
Predictability Frequency Percent (%) Cumulative percent (%)
±0.50 44 69.80 69.80
±1.00 9 14.30 84.10
±2.00 3 4.80 88.90
±3.00 4 6.30 95.20
±5.00 3 4.80 100.00
Total 63 100.00 100.00Postoperative complications and subjective symptoms
Postoperative complications are presented in Table 3.
ICLs were decentred in 3 eyes (4.34%). ICL decentration in
2 eyes was correctable with spectacles, both of these eyes
had low vault and developed anterior subcapsular cataract,
one eye lost >2 lines of preoperative BSCVA while the other
maintained BSCVA. One eye required repositioning of the
ICL which increased BSCVA to 20/30 at the last visit com-
pared to preoperative BSCVA of 20/40.One eye with Off axis
toric ICL implantation, required repositioning of the ICL.
UCVA improved to 20/40 at the last visit from 20/80 one
month postoperatively.
One eye, in a 24-year-old patient, developed a hypotony
with shallowing of the anterior chamber first day postopera-
tive. (high possibility of cyclodialysis cleft). The AC reformed
with an air bubble. The eye was also treated with atropine
drops and topical steroid was stopped. Two weeks later
IOP build-up was seen, AC became deep and anterior sub-
capsular cataract developed. The ICL was removed and phac-
Table 3. Complications in eyes that underwent implantable collamer lens
surgery for myopia.
Complication Number
of eyes (%)
Comment
ICL decentration 3(4.34) 1 eye ICL reposition required, 2
eyes need spectacles
Off axis
implantation of
Toric ICL
1(1.4) ICL reposition required
Cataract(ASCC) 3(4.34) 2 eyes no treatment,1eye ICL
removal, Phaco + PC IOL
Cyclodialysis cleft 1(1.4) ICL removal, Phaco + PC IOL
Pupillary block 4(5.8) 2 eyes ICL removed,1eye surgical
PI,1eye yag-laser PI required
Shallow AC with
iridocorneal
touch
1(1.45) ICL removal
Incorrect ICL
power
1(1.45) ICL replacement
ASCC = anterior subcapsular cataract.
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Inc., Fort Worth, TX, USA) in the bag, The IOL implantation
was uneventful and at 6 months postoperatively, the BSCVA
returned to 20/20.
One eye (1.45%), developed a shallow anterior chamber
with iridocorneal touch that required ICL removal at 17 days
postoperatively and reimplanted with a smaller diameter ICL
(11.5–11 mm) at 5 months after initial surgery. The UCVA was
20/30 at the last visit. One eye (1.45%), with incorrect ICL
power was replaced with no loss of BSCVA.
Fourteen patients (20.3%) complained of (halo, glare,
diplopia. . .etc.) postoperatively.Intraocular pressure
The mean intraocular pressure (IOP) increased statistically
significantly from 16.16 ± 2.6 mmHg preoperatively to
21.93 ± 7.45 mmHg 4 h postoperatively (P = 0.001) (Fig. 7).
At 1 day postoperatively, the mean IOP was 16.46 ±
9.12 mmHg (P > 0.05). The mean IOP was 16.10 ± 2.6 mmHg
at the last postoperative visit (P > 0.05). At 1st day, 10
(14.49%) eyes had high IOP. Pupillary block glaucoma oc-
curred in 4 (5.8%) eyes within the first postoperative day,
all of which resolved with secondary surgical intervention.
One of the secondary surgical interventions was additional
yttrium–aluminum–garnet laser iridotomy to enlarge an exist-
ing iridotomy site. Two eyes required ICL removal, and thereFigure 7. The change in mean intraocular pressure at 4 h (33 eyes) 1 day
(67 eyes), 4 week (63 eyes), 3 months (34 eyes), 6 months (36 eyes), last
visit (65 eyes).were two surgical iridectomies. The IOP was controlled
with pressure lowering medication in 6 (8.6%) eyes. The
IOP remained within normal limits in all eyes after secondary
surgical or medical intervention. No patients in this study
required long-term glaucoma medication, and there was no
significant late elevation of IOP after implantation of the
ICL for myopia.
Endothelial cell density (cells per square millimeter)
Table 4 shows the endothelial cell density. The preopera-
tive endothelial cell density was significantly greater than at
the last postoperative visit (P < 0.0001), which implies the
expected endothelial cell loss due to surgery.
When endothelial cell loss was represented as a percent-
age of the preoperative value, the mean loss was 5.6%
(range, 0.15–26.23%).
Discussion
Phakic IOLs are an effective treatment for the correction of
myopia and have significant advantages such as reversibility,
immediate correction, stability, and relative simplicity. How-
ever, some studies describe complications with these lenses.
UCVA, the primary efficacy variable for this study and
most refractive surgeries, showed significant improvement
over preoperative values. For example, UCVA improved by
12 lines by the last postoperative visit. Additionally vision
recovered quickly, with UCVA improving by the first postop-
erative week and remaining stable throughout the follow-up
period. This outcome supported the value of the implantable
lens concept. UCVA of 20/40 or better increased from 0% of
eyes preoperatively to 86.2% at the last postoperative visit.
The proportion of eyes with 20/20 or better also showed a
substantial improvement, increasing from 0% preoperatively
to 49.20% at the last postoperative visit. These results are
similar or better than those reported in previous ICL studies.
Vukich et al.,21 reported the proportion of eyes 20/20 or bet-
ter was 60.1% at 1 year compared to our study (49.2%). Vuk-
ich et al.,21 reported (92.5%) of eyes with 20/40 or better,
whereas Menezo et al.28 (76.19%), Fernandez et al.24
(44.4%) and Uusitalo et al.25 (52.6%) reported lower UCVA
than our study (86.2%) (Table 5).
In our study, a modified PPC IOL, the ICL, effectively
reduced high myopia. We found a different level of efficacy
than in other published studies. Limitations in predictability
are partly related to the selection of the phakic IOL power
based on spectacle refraction. It is well known that refraction
may be less reliable in eyes with more extreme levels of myo-
pia. In our study, 69.8% of eyes had an SE within ± 0.50 D of
emmetropia and 84.1% had an SE within ± 1.00 D. Vukich et
al.21 reported 61.6% of eyes with an SE within ±0.50 D and
84.7% within ±1.00 D, Zaldivar et al.33 report 69% ± 1.00 D
and 44% within ±0.50 D, Assetto et al.34 reported 31% within
±1.00 D, and Pesando and coauthors30 report 52.53% within
±1.00 D, while Uusitalo et al.25 and Fernandez et al.24 report
71.1% and 22.2% within ±0.50 D and 81.6% and 56.9% withinTable 4. Endothelial cell density (cells/mm2).
Exam Mean ± SD Eyes % Loss P value
Preoperative 2784.7 ± 301.5 54 – <0.0001
Postoperative 2614 ± 336.4 54 5.6%
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264 N. Al Sabaani et al.±1.00 D, respectively. The wide range of outcomes
indicates the need for greater accuracy in ICL power calcula-
tions. One alternate is combining phakic IOL implantation
with laser in situ keratomileusis or photorefractive
keratectomy (bioptics) to improve the final visual
outcome.46–48 In our study no eye underwent bioptics for
residual refractive error.
Sanders et al.35 reported an improvement in BSCVA after
ICL implantation with no accompanying intraoperative or
postoperative complications. Preservation of BSCVA, com-
monly considered the primary criterion for assessing the
safety of a refractive surgical procedure, was extremely high
in the study cohort presented in this article. Not only mainte-
nance but also an improvement in BSCVA (20/20 or better)
was achieved at last visit (64.6%) compared with preoperative
levels (31.9%). Only one eye (1.5%) lost more than 2 lines of
BSCVA postoperatively. This loss of BSCVA was due to a dec-
entered lens with low vault (80um) that developed and ante-
rior subcapsular cataract. At the last visit her BSCVA was 20/
60. Previously published ICL reports have also documented
an improvement in BSCVA after ICL implantation. BSCVA
was maintained or improved in all eyes in the series published
by Gonvers et al,27 Menezo et al.28 and Pesando et al.30
whereas only one eye lost BSCVA in studies by Assetto et al34
and Zaldivar et al.33 Loss of BSCVA (P2 lines) in the current
study occured in 1 eye (1.5%) for all postoperative visits
which was similar to Sanders et al23 who reported three cases
(1.6%) that lostP2 lines of BSCVA at 1 year postoperatively.
Vukich and coauthors21 reported 7 eyes (1.3%) lost P2 lines
of BSCVA 6 months or later. According to our results, PPC
IOL (ICL) implantation appears to be safe; BSCVA improved
2 lines in 10.7% of eyes and more than 2 lines in an additional
9.2% of eyes at the last postoperative visit. This gain could be
the result of postoperative magnification of the retinal image
by eliminating the spectacle-induced minification experi-
enced by high myopes.
Furthermore, as previously reported in the literature, the
safety of the ICL procedure is enhanced by the low incidence
of postoperative and intraoperative complications.33,35,36
Secondary surgeries, adverse events, and surgical complica-
tions, as anticipated, were rare in our study. Intraoperatively
there were only 3 cases (4.3%) with haptic tear and only 1
case (1.4%) with a cracked optic during ICL insertion, which
could be related to the surgical learning curve.
The complications observed after ICL implantation
occurred during the early postoperative period, with an
absence of any long-term complications. Postoperative com-
plications included one eye with hypotony and flat anterior
chamber with high possiblility of cyclodialysis cleft day one
postoperatively which was not previously reported, one with
a shallow anterior chamber with iridocorneal touch which was
treated by replacing the ICL with a smaller diameter ICL.
These complications occurred during the early phase of our
experience with ICL implantation at our institute and
data from trainees are included in this study. Hence, the
surgical learning curve might have been a factor in these
complications.
Acute elevation in IOP that required secondary surgical
intervention occurred in 4 eyes (5.8%) in the early postoper-
ative period due to small or insufficient laser iridotomies or
high vault. These were managed effectively by laser iridoto-
mies, surgical iridectomies or ICL removal due to high vault
Outcome of phakic ICL for myopia 265with shallow anterior chamber. All eyes of elevated IOP
returned to normal range after surgical or medical interven-
tion. Of note, no patients in the study cohort required
long-term glaucoma medication, and there was no significant
late elevation in IOP after implantation of the ICL for myopia.
Vukich et al21, reported that 21 eyes (4.0%) required second-
ary surgical intervention for management of acute pressure
rise one month postoperatively. In a report by Zaldivar et al33
of 124 eyes ICL implantation, 14 eyes had IOP spikes greater
than 26 mmHg. Of the 6 eyes with pupillary block glaucoma,
4 eyes had not received peripheral iridotomies preopera-
tively. The iridotomies in the other 2 cases were presumably
closed.33 The 6 eyes were treated by postoperative laser irid-
otomies, but the timing of these postoperative spikes was
not provided.33 Fernandez et al24 reported 2 of 18 eyes
(11.1%) developed pupillary block with an IOP of
40–50 mmHg at one day postoperatively. In both eyes, 1 of
the iridotomies was too small.24 After the iridotomies were
enlarged, the IOP returned to preoperative values.24 Uusitalo
et al25, reported that pupillary block glaucoma caused by clo-
sure or insufficiency of the laser iridotomies requiring surgical
intervention occurred in 3 eyes (7.9%) within the first 2 days
postoperatively.
Cataract formation is a potential complication in any
intraocular procedure. In our study, there were 3 eyes with
anterior subcapsular cataracts (4.34%). Two eyes had low
vault, while the third case developed hypotony, flat AC with
high possibility of cyclodialysis cleft that led to the develop-
ment of visually significant anterior subcapsular cataract. In
the third eye, we elected to explant the ICL and extract the
lens with PC IOL implantation and the postoperative BSCVA
was 20/20.
Evaluation of ICL-induced cataracts is difficult for several
reasons. First, any trauma to the crystalline lens during laser
iridotomy or surgical implantation must be ruled out, which
we cannot exclude due to the retrospective nature of our
study. Secondly a cataract can develop over a long period
of time. Gonvers et al42 found that the rate of anterior sub-
capsular cataracts increased with the duration of follow-up.
They found it was 27% (20 of 75 eyes) at one year or more
and 33% at 24 months or more, and 38% at 30 months or
more.42 This delay between implantation and the develop-
ment of a cataract may explain why most studies with a short
follow-up do not report this complication.32,34,35 In our series
with short follow-up (minimum 6 month), we found a rate of
4.34%. Longer term follow-up may be necessary to fully eval-
uate the real risk of ASCC. Over a span of 3 years, Zaldivar
et al37 found an 8.5% rate of cataract development with dif-
ferent generations of ICLs, and in a series of 12 ICLs, Menezo
and coauthors28 report 3 anterior subcapsular cataracts
occurring at 19, 20, and 21 months, respectively. Vukich et
al.,21 reported 14 eyes (2.7%) of ASCCs, 12 eyes (1.9%)
occurring early (690 days postoperatively) and 2 eyes
(0.40%) occurring late (P1 year postoperatively). Sander
et al.41 studied 526 eyes, which were followed for an average
of 4.7 years to evaluate the incidence of asymptomatic and
clinically significant anterior subcapsular opacities and found
that approximately 6–7% of eyes develop anterior subcapsu-
lar opacities at 7 + years following ICL implantation but only
1% to 2% progress to clinically significant cataract during the
same period, especially very high myopes and older patients.
Galeana et al43 reported an 8% (14 of 170 eyes) incidence oflens opacities after ICL implantation. Lackner and coauthors44
found that the lens opacifications developed in 25 of 75 eyes
(33.3%), 14 eyes(18.7%) showed progressive opacification,
and 11 eyes (14.7%) remained stable with 8 eyes (10.7%)
requiring cataract surgery. Sanders and Vukich38 compared
the STAAR V3 ICL to the V4 lens, which has a more anterior
vault. They found significantly fewer anterior subcapsular
opacities with the V4 lens (2.9% vs 12.6% with the V3 lens).
The older model (V3) was associated with greater late opac-
ities (appearing later than 1 year postoperatively) (9.2% with
the V3 vs 0.6% with the V4).
The latest generation of myopic ICLs (model V4) is pre-
sumed to completely vault the anterior crystalline lens cap-
sule and to rest on the anterior zonular fibers. This, of
course, necessitates correct selection of the overall size of
the ICL, which ranges from 11.5 to 13.5 mm. To date, the
ICL size can only be estimated and is considered to be appro-
priate when equal to the horizontal diameter of the cornea
(white-to-white distance) plus 0.5 mm. In our study, different
methods (Caliper, Orbscan, UBM) were used to measure
white-to-white distance. Further studies are required to
determine the most accurate method of measuring the hori-
zontal corneal diameter.
It is well known that any intraocular surgical procedure
that affects the anterior segment provokes endothelial cell
loss, and the decrease of endothelial density is proportional
to the surgical time and manipulation.39 Thus one of the main
parameters used to evaluate the safety of an anterior seg-
ment surgical technique is the endothelial cell density. In
our study, the endothelial cell density loss at the last postop-
erative visit was 5.6%, the progressive cell loss cannot be
determined in our study due to the retrospective nature of
this study and the single postoperative measurement done
at the last visit. Also the long-term effect the ICL on the cor-
neal endothelium requires longer follow-up. Ruhswurm et al40
reported continuous endothelial cell loss after ICL implanta-
tion during a 4-year follow-up, with mean endothelial cell loss
preoperatively of 1.8% at 3 months, 4.2% at 6 months, 5.5%
at 12 months, 7.9% at 2 years, 12.9% at 3 years, and 12.3%
at 4 years. Other endothelial cell characteristics remained sta-
ble throughout the duration of follow-up. The investigators
concluded there was rapid cell loss until 1 year postopera-
tively, after which the rate of loss was no longer statistically
significant. Jimenez-Alfaro et al.45 found the majority of cell
loss (4.41%) occurred at 6 months postoperatively.
Fernandez et al24 found the endothelial cell density loss at
6 months was 4.91% and did not progress over time,
suggesting that the initial loss was related to surgical trauma.
Arne49 found that the mean postoperative endothelial cell
loss was 2.1% at 3 months, 2.3% at 6 months, 2.0% at 1 year,
and 2.0% at 2 years. The variable outcomes indicate that
long-term follow up is required to evaluate endothelial cell
loss accurately.
In conclusion as the follow-up in our study was relatively
short, we cannot be certain of the long-term safety of this
procedure. We have demonstrated excellent predictability,
efficacy, and good visual results with few short-term compli-
cations. Hypotony with very shallow AC with high possibility
of Cyclodialysis cleft and cataract formation is the most
severe complication we have experienced, and we believe
long term studies are warranted to determine the long-term
safety of ICL implantation.
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